OnKure Therapeutics, Inc.
NASDAQ:OKURBiotechnology
+$0.01 today
- Market cap
- $114.22M
- Beta
- 0.28
- P/E (TTM)
- -1.0
- EPS (TTM)
- -$4.30
Volume 0.17M
Average 0.37M
OKUR Common Stock Issued
Cash raised by issuing new shares.
OnKure Therapeutics, Inc.NASDAQ: OKUR
Common Stock Issued · Q1 FY2026 · quarter ended Mar 2026
Common stock issued turns positive
Q1 FY2026 common stock issued was $146M, compared with -$37K a year earlier. Trailing-twelve-month common stock issued was $146.24M. Over 3 fiscal years it compounded at -15.8% a year.
Context
- Common stock issued increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly common stock issued holds near $146M or moves back toward the trailing-twelve-month quarterly average of $36.56M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Common Stock Issued history
USD · from the cash flow
- Latest · FY2025
- 203K USD
- Year-over-year change
- -99.7%
- 4-year CAGR
- -80.2%
| Period | Period end | Common Stock Issued | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 203K | -99.7% |
| FY2024 | 2024-12-31 | 58.91M | +90526.2% |
| FY2023 | 2023-12-31 | 65K | -80.9% |
| FY2022 | 2022-12-31 | 340K | -99.7% |
| FY2021 | 2021-12-31 | 132.41M | — |
Common Stock Issued vs competitors
How OKUR compares with its peers on the latest reported figures
- OKUR's LTM Mar 2026 common stock issued of $146.24M is the largest of the 4 companies compared; the peer median is $29.95M.
- Its year-over-year change of +148.3% is the 3rd highest of 4, against a peer median of +187.9%.
- Over three fiscal years its annual growth of -15.8% compares with a peer median of +845.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
OKUROnKure Therapeutics, Inc. | LTM Mar 2026 | $146.24M | +148.3% | -15.8% | — |
| LTM Mar 2026 | $120.16M | +1535.2% | +1663.7% | 224.7% | |
| LTM Mar 2026 | $29.95M | +187.9% | +27.3% | — | |
| LTM Jun 2026 | $0 | -100.0% | — | 0.0% | |
| Peer median (excluding OKUR) | $29.95M | +187.9% | +845.5% | 112.3% | |
Competitors are the stored peer set for OKUR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (39.77M) | (29.51M) | (35.31M) | (52.67M) | (59.52M) |
| Depreciation & Amortization | 50K | 387K | 560K | 662K | 830K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 0 | 48K | 199K | 4.53M | 11.63M |
| Change in Working Capital | (2.8M) | 2.12M | 6K | (3.95M) | (4.78M) |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 0 | 0 | 1.71M | (5.93M) | (4.55M) |
| Other Working Capital | (2.8M) | 2.12M | (1.71M) | 1.98M | (235K) |
| Other Non-Cash Items | 4.54M | 0 | 0 | 316K | 6K |
| Operating Cash Flow | (37.98M) | (26.95M) | (34.55M) | (51.12M) | (51.83M) |
| Capital Expenditures | (198K) | (1.13M) | (246K) | (52K) | (46K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | (31.41M) | 0 | 0 | 0 | 0 |
| Sales of Investments | 8.23M | 44.1M | 0 | 15.93M | 0 |
| Other Investing Activities | 0 | (44.1M) | 0 | 0 | 0 |
| Investing Cash Flow | (23.38M) | (1.13M) | (246K) | 15.87M | (46K) |
| Debt Repayment | 0 | 0 | 0 | 6M | 0 |
| Common Stock Issued | 132.41M | 340K | 65K | 58.91M | 203K |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | (1.38M) | (723K) | 51.22M | (40K) |
| Financing Cash Flow | 132.41M | 26.47M | 53.13M | 116.13M | 163K |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 71.05M | (1.62M) | 18.33M | 80.89M | (51.71M) |
| Free Cash Flow | (38.18M) | (28.09M) | (34.79M) | (51.17M) | (51.87M) |
OnKure Therapeutics, Inc.
NASDAQ:OKUR
Intrinsic Alpha fair value
Locked
Current Price
$2.82
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.